Cell Rep:新方法有望缓解化疗导致的疼痛

2018-05-30 周舟 新华社

美国研究人员29日说,他们发现一种能够从根源上阻断疼痛的新方法,有望缓解因癌症化疗导致的疼痛。

美国研究人员29日说,他们发现一种能够从根源上阻断疼痛的新方法,有望缓解因癌症化疗导致的疼痛。

发表在美国《细胞报告》杂志上的新研究显示,向小鼠脊髓中注射一种天然蛋白质“载脂蛋白A-I结合蛋白”,可抑制和逆转与疼痛产生过程有关的炎症反应及细胞活动。疼痛缓解效果可持续约两个月,且不影响小鼠的运动机能。

研究人员解释说,“载脂蛋白A-I结合蛋白”此前已被用于治疗动脉粥样硬化。最新研究表明,它还可以抑制位于细胞表面的“Toll样受体4”,后者能像天线一样“搜寻”感染或组织损伤的信号,与疼痛相关。

论文共同作者、加利福尼亚大学圣迭戈分校医学院麻醉学系教授托尼·雅克斯说,阿片类药物仅仅抑制疼痛感,引发疼痛的源头依旧存在。而他们的方法“抑制了引起疼痛的潜在机制,而不是掩盖症状”,“实际上改变了疼痛产生的过程本身”。

原始出处:

Sarah A. Woller, Soo-Ho Choi, Eun Jung An, et.al. Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. Cell Reports Volume 23, Issue 9, p2667–2677, 29 May 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870669, encodeId=dabf18e06695b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 23 06:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903330, encodeId=c578190333045, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 16 20:47:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960938, encodeId=33241960938b1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 14 13:47:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320191, encodeId=fb85320191a3, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 31 07:15:07 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320105, encodeId=30c8320105b3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 31 01:01:45 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870669, encodeId=dabf18e06695b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 23 06:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903330, encodeId=c578190333045, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 16 20:47:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960938, encodeId=33241960938b1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 14 13:47:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320191, encodeId=fb85320191a3, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 31 07:15:07 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320105, encodeId=30c8320105b3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 31 01:01:45 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870669, encodeId=dabf18e06695b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 23 06:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903330, encodeId=c578190333045, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 16 20:47:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960938, encodeId=33241960938b1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 14 13:47:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320191, encodeId=fb85320191a3, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 31 07:15:07 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320105, encodeId=30c8320105b3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 31 01:01:45 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2019-03-14 hb2008ye
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870669, encodeId=dabf18e06695b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 23 06:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903330, encodeId=c578190333045, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 16 20:47:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960938, encodeId=33241960938b1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 14 13:47:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320191, encodeId=fb85320191a3, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 31 07:15:07 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320105, encodeId=30c8320105b3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 31 01:01:45 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 kafei

    学习了谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1870669, encodeId=dabf18e06695b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Dec 23 06:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903330, encodeId=c578190333045, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 16 20:47:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960938, encodeId=33241960938b1, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 14 13:47:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320191, encodeId=fb85320191a3, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 31 07:15:07 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320105, encodeId=30c8320105b3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Thu May 31 01:01:45 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 yfjms

    学习

    0

相关资讯

Cell Death Dis:研究首次发现Corylin具有抗肿瘤活性

Corylin是一种从补骨脂中提取的生物活性物质,可促进骨骼分化并抑制炎症。到目前为止,仅有少数研究探究了corylin的生物学调节功能,尚未有研究调查其抗肿瘤活性。在这项研究中,我们使用细胞功能分析来分析Corylin在肝细胞癌(HCC)中的抗肿瘤活性。此外,进行全转录组测定以鉴定由corylin调节的下游基因,并且进行功能获得和功能丧失实验以检查上述基因的调节作用。结果发现,corylin可显

CLIN CANCER RES:血浆代谢组学分析预测非小细胞肺癌化疗效果

目前尚无得到验证的可以鉴别能从化疗中获益的肺腺癌患者的分子标志。CLIN CANCER RES近期发表了一篇文章,研究以代谢组学分析为基础的可以预测一线化疗效果和患者生存结果的分子标志模型。

JACC:卡维地洛可用于预防化疗引起的心脏毒性

蒽环霉素(ANT)化疗有一定的心脏毒性,β受体阻滞剂预防该心脏毒性的效果尚存在争议。本研究的目的旨在通过随机双盲对照试验评估卡维地洛在预防ANT致心脏毒性中的作用。本研究纳入了200例HER2阴性且左室射血分数正常的接受ANT化疗的乳腺癌患者,并将其随机分成卡维地洛治疗组和安慰剂组,主要终点事件是6个月内LVEF减少10%以上,次要终点事件是卡维地洛对肌钙蛋白I和B型钠尿肽的影响和心脏舒张功能不全

郭瑞霞教授:妊娠滋养细胞肿瘤,可被化疗攻克的癌症

妊娠滋养细胞肿瘤是胚胎的滋养细胞发生恶变而形成的肿瘤,有一半由葡萄胎恶化发展而来。因人种的差异,其在黄种人的发病率要高于其他人种,随着我国二孩政策开放,高龄妊娠妇女增加,近年发病率又有抬头趋势。因为妊娠滋养细胞肿瘤对化疗的高度敏感性,使之成为迄今为止化疗治疗效果最好的肿瘤,疾病缓解率可达80%以上,即将被攻克。

JCO:Osimertinib比化疗有利于改善晚期非小细胞肺癌患者的状态

在评估新的肿瘤治疗策略的总临床获益时,患者报告的结局数据很重要。JCO近期发表了一篇文章,评估接受Osimertinib或化疗治疗的晚期非小细胞肺癌患者报告的症状区别。

JNCI:这道早期乳腺癌化疗的“减法题”,21基因检测教你做

如何平衡乳腺癌治疗疗效与乳腺癌患者的经济负担是临床工作者常常面对的一个问题。各种评估预后的临床病理模型及基因工具能够帮助医生们更准确地估计个体辅助化疗的获益程度。基因工具的广泛应用到底是否改变了医生的临床决策及患者的治疗方案?这篇发表在JNCI的文章就介绍了基因工具近年来带来的豁免化疗的新风向。